News
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in the New England Journal of Medicine — followed 751 people across the U.
However, Wegovy is also licensed for other conditions – such as preventing heart attacks – while the equivalent trials with Mounjaro have not been completed. Weight-loss drug approved for ...
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results